The combination of PD-L1 inhibitors (eg, pembrolizumab) and TKIs (eg, lenvatinib) in patients with malignant tumors was more effective than single drug [89], suggesting that the combination therapy was an important development direction for future tumor therapy. Here, CD274 is linked to cancer.